Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Krka DDFRA:KN8 -5.30%71 5-Year Yield-on-Cost % is 6.86 as of Aug. 13, 2026, which is 27% below its 10-year median of 9.41. GuruFocus rates FRA:KN8 with a GF Score™ of 71/100 and a GF Value™ of €206.26 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 511 Drug Manufacturers companies, Krka DD ranks better than 81.8% on this metric.
Krka DD's yield on cost for the quarter that ended in Jun. 2026 was 6.86.
The historical rank and industry rank for Krka DD's 5-Year Yield-on-Cost % or its related term are showing as below:
FRA:KN8'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 6.02 Med: 9.41 Max: 12.83
Current: 6.86
During the past 13 years, Krka DD's highest Yield on Cost was 12.83. The lowest was 6.02. And the median was 9.41.
FRA:KN8's 5-Year Yield-on-Cost % is ranked better than 81.8% of 511
companies
in the Drug Manufacturers industry
Industry Median: 2.28
vs FRA:KN8: 6.86
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Krka DD 5-Year Yield-on-Cost % Related Terms
FRA:KN8 vs ZTS, UTHR, VTRS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Krka DD's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krka DD 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Krka DD's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Krka DD's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Krka DD is calculated as
Krka DD (FRA:KN8) has a 5-Year Yield-on-Cost % of 6.86 as of Aug. 13, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Krka DD and its competitors. This is 27% below median its historical median of 9.41. Over the past decade, Krka DD's 5-Year Yield-on-Cost % has ranged from 6.02 to 12.83. According to the industry distribution chart, Krka DD ranks #93 out of 511 companies in the Drug Manufacturers industry, placing it in the top 18.2%.
Is Krka DD's 5-Year Yield-on-Cost % too high?
Krka DD's current 5-Year Yield-on-Cost % of 6.86 is 27% below median its 10-year median of 9.41. Over the past 10 years, this metric has ranged from a low of 6.02 to a high of 12.83. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.28. Krka DD's value of 6.86 is 200.9% above this industry median. Based on the distribution chart, Krka DD ranks #93 out of 511 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Krka DD has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krka DD's 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Krka DD ranks #93 out of 511 companies for 5-Year Yield-on-Cost %. This places Krka DD in the top 18% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 2.28. Krka DD's value of 6.86 is 200.9% above this benchmark. Historically, Krka DD's own 5-Year Yield-on-Cost % has ranged from 6.02 to 12.83 over the past decade. While the company's 10-year median is 9.41 vs. the industry median of 2.28, Krka DD has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.28, based on 511 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Krka DD's current 5-Year Yield-on-Cost % of 6.86 is 200.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Krka DD and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Krka DD's current 5-Year Yield-on-Cost % is 6.86, which is 27% below median its own 10-year median of 9.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krka DD stock overvalued right now?
Based on GuruFocus' analysis, Krka DD (FRA:KN8) is currently considered Modestly Overvalued. The stock's GF Value™ is €206.26, compared to a current price of €250.00 — trading 21.2% above its estimated fair value. The current 5-Year Yield-on-Cost % is 6.86, which is 27% below median its 10-year median of 9.41 and 200.9% above the Drug Manufacturers industry median of 2.28. Krka DD's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Krka DD (FRA:KN8), the current 5-Year Yield-on-Cost % is 6.86 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krka DD (FRA:KN8) Overvalued in 2026?
Based on GuruFocus' analysis, Krka DD stock appears to be overvalued.
The current stock price of €250.00 is trading 21.2% above its estimated GF Value™ of €206.26.
GuruFocus considers Krka DD to be Modestly Overvalued.
Key valuation signals for FRA:KN8:
5-Year Yield-on-Cost %: 6.86 (27% below median its 10-year median of 9.41)
GF Value™: €206.26 vs. price of €250.00 (21.2% above fair value)
Industry Position: 200.9% above the Drug Manufacturers median (#93 of 511)
No single metric tells the full story. See the FRA:KN8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krka DD engages in the development, production, marketing, and sales of human health products (prescription pharmaceuticals and non-prescription products), animal health products, health resorts, and tourist services. The company's products in Prescription pharmaceuticals include Cardiovascular diseases, Infections, and Oncology; Non-prescription products include Cold and cough products, nasal products, vitamins and minerals, and hair care products; and Animal health products include Antimicrobials and disinfectants, among others. It operates across the European Union, South-East Europe, Eastern Europe region, and Others. The company derives a majority of its revenue from the European Union.
71GF Score
Get the complete analysis for FRA:KN8
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:KN8 has been successfully added to your 
